A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 460
- 试验地点
- 15
- 主要终点
- Event Free Survival (EFS)
研究概览
简要总结
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
详细描述
Following validation of eligibility criteria, patients will be randomised (1:1:1:1) to receive:
- Arm A: Standard radiotherapy then follow-up
- Arm B: Tailored radiotherapy and ATRA (Vesanoid)
- Arm C: Standard radiotherapy and ATRA (Vesanoid)
- Arm D: Tailored radiotherapy then follow-up
This randomised phase III clinical trial will provide the clinical proof-of-concept that unilateral irradiation for lateralized tumors and the addition of ATRA (Vesanoid) to radiotherapy in HNSCC prevents severe lymphopenia and immunosenescence and therefore, may foster a radiation-induced anticancer immune response sufficient to increase event-free survival at 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥ 18 years old at time of inform consent signature.
- •Patients with primary head and neck tumour up to, but not crossing the midline, previously untreated with histologically-confirmed squamous cell carcinoma of:
- •the oropharynx p16-, larynx or hypopharynx : T1/N2a-N2b, T2/N0-N2b, T3/N0-N2b (UICC 8th Ed.), or
- •the oropharynx p16+ : T1/N1 (multiple nodes), T2-T3/N0-N1 (UICC 8th Ed.).
- •Patients with lymph node staging assessed by an FDG-PET/CT with no contralateral nodal uptake.
- •Patients amenable to treatment with RT or concomitant chemo-radiotherapy as decided by the treating physician as a function of tumor stage, tumor location, performance of the patients.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or
- •Adequate hematologic and end-organ function, defined by the following laboratory test results obtained within 7 days prior to randomisation :
- •Hematological (without transfusion within 2 weeks) :
- •Neutrophils count > 1.5 × 109 /L
- •Platelets count > 75 × 109 /L
- •WBC≥ 3.0 × 109 /L
- •Hepatic function :
- •Total Bilirubin < 1.5 × ULN (except for Gilbert's syndrome which will allow bilirubin ≤ 3 ULN).
- •Alanine aminotransferase (ALT) ≤ 2.5 × ULN.
- •Aspartate aminotransferase (AST) ≤ 2.5 × ULN.
- •Albumin >3.0g/dL
- •Renal function :
- •Serum creatinine < 1.5 ×ULN.
- •QTcF ≤450ms for men and 470ms for women, from 3 electrocardiograms on screening ECG, within 7 days prior randomisation.
- •Women patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test within 7 days prior randomisation, and agrees to use adequate contraception for up to 1 month after the end of study treatments.
- •Fertile men must agree to use an effective method of contraception during the study and for up to 1 month after the end of study treatments.
- •Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.
- •Patients must be covered by a medical insurance in country where applicable.
排除标准
- •Patient with primary tumor crossing the midline or patients with bilateral primary tumors.
- •Patients with T1-N0 (p16-), T1-N1 (p16-), T1-N0 (p16+), T4 (p16- and p16+), bilateral lymph nodes or nodal disease more than 6 cm (p16- and p16+).
- •Patients with unknown primary tumor size as per TNM i.e. T0-N1 to T0-N3, p16- or p16+.
- •Patients with contralateral FDG-PET/CT nodal uptake.
- •Patient with any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental).
- •Patient with malignancies other than HNSCC within 3 years prior to randomisation with the exception of adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localised prostate cancer treated surgically with curative intent.
- •Patient with ongoing or anticipation of need for systemic immunosuppressive medication (including, but not limited to, glucocorticoids, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents); with the exceptions of intranasal, inhaled or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •Patient with ongoing or anticipation of need for systemic immunostimulatory agents (including, but not limited to, interferons and IL-2).
- •Patient with concurrent treatment with any other anti-cancer treatment, approved or investigational agent or participation in another clinical trial with therapeutic intent.
- •Patient with infectious diseases :
- •Severe infection within 4 weeks prior to randomisation, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia,
- •Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening),
- •Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA at screening,
- •HIV infection,
- •Active tuberculosis.
- •E11.Patient with any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •Patient with known hypersensitivity to tretinoin, other retinoids, soya, peanut or to any of the excipients of vesanoid.
- •Patient with known malabsorption syndrome and/or unable to swallow oral medication.
- •E14.Patient with ongoing or expected need for concomitant treatment with vitamin A, tetracyclines, other retinoids, anti-fibrinolytic agent, and strong inducers or inhibitors of CYP3A
- •E15.Pregnant or lactating woman.
研究组 & 干预措施
Standard radiotherapy
Patient will receive 6 to 8 weeks of standard (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Standard radiotherapy (Radiation)
Standard radiotherapy
Patient will receive 6 to 8 weeks of standard (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Cisplatin (Drug)
Standard radiotherapy
Patient will receive 6 to 8 weeks of standard (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Cetuximab (Drug)
Tailored radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). Then, patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy. In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments). Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Vesanoid (Drug)
Tailored radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). Then, patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy. In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments). Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Tailored radiotherapy (Radiation)
Tailored radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). Then, patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy. In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments). Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Cisplatin (Drug)
Tailored radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). Then, patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy. In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments). Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Cetuximab (Drug)
Standard radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).Then, patient will receive 6 to 8 weeks of standard (chemo)radiotherapy. Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Vesanoid (Drug)
Standard radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).Then, patient will receive 6 to 8 weeks of standard (chemo)radiotherapy. Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Standard radiotherapy (Radiation)
Standard radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).Then, patient will receive 6 to 8 weeks of standard (chemo)radiotherapy. Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Cisplatin (Drug)
Standard radiotherapy and ATRA (Vesanoid)
ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).Then, patient will receive 6 to 8 weeks of standard (chemo)radiotherapy. Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
干预措施: Cetuximab (Drug)
Tailored radiotherapy
Patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Tailored radiotherapy (Radiation)
Tailored radiotherapy
Patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Cisplatin (Drug)
Tailored radiotherapy
Patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).
干预措施: Cetuximab (Drug)
结局指标
主要结局
Event Free Survival (EFS)
时间窗: At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years
Event free survival (EFS) is defined as the time from randomisation to apparition of a documented relapse either local or regional or distant according to clinical or radiological assessment, or persistent residual disease including pathologically positive neck node, or death due to any cause.
次要结局
- Local relapse Free Survival(At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years)
- Regional relapse Free survival(At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years)
- Metastasis Free Survival(At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years)
- Rate of pathologically positive lymph nodes(At 4 months from the completion of (chemo)-radiotherapy)
- Event Free Survival (EFS)(At 4 months from the completion of (chemo)-radiotherapy)
- Overall survival(Until up to 2 years follow-up of the last patient enrolled)
- Adverse events(From the date of first intake of study drug until 27 months after the randomisation of the last randomised patient)
- Patient quality of life (EORTC QLQ-C30)(At randomisation, at 6, 9, 15, 21 and 27 months after randomisation and30 days after the last study treatments administration)
- Patient quality of life (EQ5-DL)(At randomisation, at 6, 9, 15, 21 and 27 months after randomisation and30 days after the last study treatments administration)
- Patient quality of life (EORTC QLQ-H&N43)(At randomisation, at 6, 9, 15, 21 and 27 months after randomisation and30 days after the last study treatments administration)
- Health economic analysis(From the first patient enrolled to 2 years after treatment discontinuation of the last patient enrolled)
- Immunomonitoring(Cycle 1 Day 1 pre-dose of Vesanoid, Day 1 of radiotherapy and end of radiotherapy (8 to 10 weeks after randomisation))